United States, Nevada, Las Vegas, DelveInsight’s ‘Diabetic Nephropathy Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Nephropathy pipeline domain.
Key Takeaways from the Diabetic Nephropathy Pipeline Report
Diabetic Nephropathy Overview
Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It is also known as Diabetic Kidney Disease (DKD). It happens when elevated blood glucose levels damage a person’s kidneys.
Diabetic nephropathy is a leading cause of chronic kidney disease and end-stage renal disease (ESRD). The kidneys in ESRD can no longer satisfy everyday life’s demands. Kidney failure can result from ESRD, which can be life-threatening.
Diabetic Nephropathy Pipeline Analysis: Drug Profile
AUP 16: Aurealis Therapeutics
Finerenone (BAY94-8862), a Nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer commenced a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III FIDELIO-DKD study in September 2015 to investigate the safety and efficacy of Finerenone in addition to standard of care in subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease. This trial was completed in April 2020. During the start of 2021, the company announced about their New Drug Application (NDA) and granted Priority Review. The findings from the Phase III FIDELIO-DKD study, which were presented in detail at the American Society of Nephrology’s (ASN) Kidney Week Reimagined 2020 and subsequently published in the New England Journal of Medicine in October 2020, were used to support this regulatory filing.
Discover more about the emerging Diabetic Nephropathy drugs @ Diabetic Nephropathy Treatment Drugs
Diabetic Nephropathy Key Companies
Diabetic Nephropathy Pipeline Therapies
Diabetic Nephropathy Pipeline Therapeutics Assessment
Scope of the Diabetic Nephropathy Pipeline Report
Find out more about the Diabetic Nephropathy treatment options in development @ Diabetic Nephropathy Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies in the Diabetic Nephropathy pipeline segment.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/